This article was contributed by Oncology Dietitian and Clinical Exercise Physiologist, Hannah Manella, MS, RD, LDN, ACSM-CEP, CET (Rush University Cancer Center). There is no
Read More >
What is COVID-19/coronavirus disease? The novel SARS-CoV-2 coronavirus that has recently been in the news is a virus that has not been previously identified. The
Read More >
Due to an increase in new and effective treatments, outcomes among lymphoma patients have improved, with a 10-year survival rate reported to be higher than
Read More >
Cancer is one of the costliest conditions to treat today in the United States. With outcomes among patients with lymphoma improving, managing costs related to
Read More >
This approval expands the use of acalabrutinib, which received accelerated approval from the FDA for the treatment of adult patients with mantle cell lymphoma (MCL).
The U.S. Food and Drug Administration (FDA) announced it has approved the use of zanubrutinib (BRUKINSA, BeiGene, Ltd.) for adult patients with mantle cell lymphoma (MCL) who have received at least on prior therapy.
Read More >Pegfilgrastim-bmez (Ziextenzo, Sandoz) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia for patients with nonmyeloid malignancies who are receiving myelosuppressive anti-cancer therapy.
Read More >
The Lymphoma Research Foundation is aware that the supply of the vital chemotherapy medicine vincristine [Oncovin] may be limited in certain areas of the country.
Read More >The U.S. Food and Drug Administration (FDA) requested the voluntary recall from Allergan in reference to the company’s Biocell textured implants linked to breast implant-associated
Read More >On July 23, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of rituximab-pvvr (Ruxience, Pfizer), a biosimilar to rituximab
Read More >
